INTRODUCTION {#s1}
============

Pleckstrin homology domain-interacting protein (*PHIP*; ENSG00000146247), located on Chromosome 6q14.1, was identified as a candidate gene for severe intellectual disability in one child in a study of 100 children with intelligence quotients (IQs) below 50 and their unaffected parents ([@WEBSTERMCS001172C4]). *PHIP* produces at least three proteins (PHIP1, PHIP, and NDRP) through alternative splicing. PHIP1 (also known as DCAF14) acts as a substrate receptor in a ubiquitin ligase pathway and mediates substrate-specific proteolysis ([@WEBSTERMCS001172C15]). Mutations affecting ubiquitin ligase pathways have been associated with a number of diseases, including neurological disorders, autoimmune disorders, and cancers ([@WEBSTERMCS001172C1]; [@WEBSTERMCS001172C19]; [@WEBSTERMCS001172C18]; [@WEBSTERMCS001172C17]). Using whole-exome sequencing (WES), we identified two novel de novo heterozygous predicted deleterious *PHIP* variants in two unrelated patients with a common phenotype of developmental delay, intellectual disability, anxiety, hypotonia, poor balance, obesity, and dysmorphic features.

RESULTS {#s2}
=======

Genomic Analysis {#s2a}
----------------

A total of 2522 patients referred to a single clinical genetic diagnostic lab (GeneDx) with developmental delay or intellectual disability were analyzed by WES. Two patients were identified with novel de novo variants in *PHIP*. WES of the two patients identified a de novo variant in the *PHIP* gene produced an average of 9.3 GB of sequence per sample. The mean coverage of captured regions was ∼120× per sample, with ∼98% covered with at least 10× coverage, an average of 92% of base call quality of Q30 or greater and an overall average mean quality score of Q36 (Supplemental Table S1).

The variants found in *PHIP* include a frameshift deletion, NM_017934.5:p.L260Wfs\*48, and a missense variant, NM_017934.5:p.F17S, located in an α-helix ([Table 1](#WEBSTERMCS001172TB1){ref-type="table"}). Neither of the variants has been observed in ExAC (Exome Aggregation Consortium; <http://exac.broadinstitute.org>, accessed in September 2015). Predictions of pathogenicity for p.F17S were variable, but the variant was predicted to be pathogenic by SIFT (Sorting Intolerant from Tolerant; [@WEBSTERMCS001172C14]), PROVEAN (Protein Variation Effect Analyzer; [@WEBSTERMCS001172C3]), MutationTaster ([@WEBSTERMCS001172C21]), and CADD (Combined Annotation-Dependent Depletion; [@WEBSTERMCS001172C13]). Cross-species comparison suggests that the phenylalanine at position 17 is highly conserved. *PHIP* has a high haploinsufficiency score \[*p*(HI) = 0.95\] ([@WEBSTERMCS001172C10]), as well as intolerance to both loss-of-function variants \[(*p*(LI) = 1.00\] and missense variants (*z*-score = 5.20) ([@WEBSTERMCS001172C5]).

###### 

Variant table

  Gene     Chromosome   NCBI reference sequence   HGVS DNA reference   HGVS protein reference   Variant type          Predicted effect   dbSNP/dbVar ID   Genotype
  -------- ------------ ------------------------- -------------------- ------------------------ --------------------- ------------------ ---------------- --------------
  *PHIP*   6q14.1       NM_017934.5               c.50T\>C             p.F17S                   Missense              Loss of function   None             Heterozygous
  *PHIP*   6q14.1       NM_017934.5               c.779delT            p.L260Wfs\*48            Frameshift deletion   Loss of function   None             Heterozygous

NCBI, National Center for Biotechnology Information; HGVS, Human Genome Variation Society; dbSNP, Database for Short Genetic Variations; dbVar, Database of Genomic Structural Variation.

Clinical Presentation {#s2b}
---------------------

Both patients with predicted deleterious de novo *PHIP* variants are females, ages 14 (Patient 1) and 8 (Patient 2), and have common features of global developmental delay, intellectual disability, anxiety, hypotonia, poor balance, obesity, and dysmorphic facial features ([Table 2](#WEBSTERMCS001172TB2){ref-type="table"}; [Fig. 1](#WEBSTERMCS001172F1){ref-type="fig"}). Both patients had normal weight at birth, but are now at or above the 97th percentile for weight and body mass index (BMI). Brain malformations are not associated with either patient.

![Facial dysmorphisms of Patient 1 showing a small, upturned nose and deep-set eyes.](WebsterMCS001172_F1){#WEBSTERMCS001172F1}

###### 

Clinical features of individuals with predicted deleterious variants in *PHIP*

  ----------------------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------
  Patient no.                                     1                                                                2                                                                                                                     de Ligt et al. (Trio 5)

  Current age (yr)                                14                                                               8                                                                                                                     UNK

  Gender                                          Female                                                           Female                                                                                                                Female

  Variant                                         c.50T\>C:p.F17S                                                  c.779delT:p.L260Wfs\*48                                                                                               c.3447T\>G:p.Y1149\*

  Prenatal issues                                 N                                                                N                                                                                                                     Meconium stained amniotic fluid

  Neonatal issues                                 N                                                                N                                                                                                                     Feeding problems

  Congenital anomalies                            Hip dysplasia                                                    Laryngeal cleft                                                                                                       N

  Dysmorphic features                             Fleshy ears, full chin, micrognathia                             Fleshy earlobes, small nose, deep-set eyes, up-turned upper lip, short and smooth philtrum, round face                Straight eyebrows, blepharophimosis, mild ptosis, long philtrum, full lips, tapered fingers, clinodactyly of the fifth finger, long toes

  Birth weight                                    WT = 3.40 kg (64%)                                               WT = 3.35 kg (60%)                                                                                                    

  Current BMI, HT, WT, OFC                        At 12 yr 10 mo:\                                                 At 8 yr 2 mo:\                                                                                                        At UNK age: BMI = 25.4 kg/m^2^\
                                                  BMI = 29.9 kg/m^2^ (z-score = 2.06)\                             BMI = 23.6 kg/m^2^ (z-score = 2.08)\                                                                                  WT = 56.8 kg (\>+2 SD)\
                                                  WT = 81.5 kg (99%)\                                              WT = 39.8 kg (97%)\                                                                                                   HT = 149.5 cm (+0.5 SD)\
                                                  HT = 165 cm (89%)\                                               HT = 129.9 cm (59%)\                                                                                                  OFC = 57.6 cm (\>+2.5 SD)
                                                  OFC = 57 cm (\>97%)                                              OFC = 49.1 cm (4%)                                                                                                    

  Obesity                                         Y                                                                Y                                                                                                                     Y

  Insulin resistance                              Y                                                                N                                                                                                                     

  Developmental delay                             Y                                                                Y                                                                                                                     Y

  Age at sitting                                  9 mo                                                             6 mo                                                                                                                  12 mo

  Age at walking                                  18 mo                                                            14 mo                                                                                                                 24 mo

  Age at talking                                  18 mo                                                            First words at 16 mo, words together by 3 yr, sentences at 4 yr, could not be understood by most people until age 5   First word at 5 yr

  Intellectual disabilities                       Y                                                                Y                                                                                                                     Y

  Full-scale IQ                                   60                                                               UNK                                                                                                                   \<50

  Current speech abilities                        Speaks in full sentences                                         Nasal speech                                                                                                          

  ADD                                             Y                                                                N                                                                                                                     

  Anxiety                                         Y                                                                Y                                                                                                                     

  Brain MRI/CT results                            Unremarkable                                                     Unremarkable                                                                                                          

  Behavioral issues                               N                                                                Y, aggressive toward siblings                                                                                         

  Regression                                      N                                                                N                                                                                                                     

  Hypotonia                                       Y                                                                Y                                                                                                                     

  Balance/coordination                            Poor                                                             Poor                                                                                                                  

  Orthopedic issues                               N                                                                N                                                                                                                     

  Gastrointestinal                                N                                                                Diarrhea, constipation                                                                                                

  Ophthalmologic issues                           N                                                                Strabismus                                                                                                            Strabismus

  Self-care abilities (e.g., dressing, feeding)   Began dressing herself at 9 yr, has trouble with buttons/shoes   Can dress, feed, and help herself but hates utensils, prefers her hands, is sloppy with brushing her hair             

  Other significant medical problems              Polycystic ovarian disease, menstrual irregularities             Headaches, sleep problems                                                                                             

  Additional genetic variants                     5q23.2 duplication, inherited                                                                                                                                                          

  Other notes:                                                                                                     Translucent skin on chest/abdomen                                                                                     
  ----------------------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------

Y, yes; N, no; UNK, unknown; mo, months; yr, years; BMI, body mass index; HT, height; WT, weight; OFC, occipital frontal circumference; %, percentile; ADD, attention-deficit disorder; SD, standard deviations.

Patient 1 has an IQ of 60, which dropped from a previous IQ of 83. In addition to obesity, Patient 1 has insulin resistance and polycystic ovarian syndrome diagnosed by an endocrinologist and treated with metformin. She has dysmorphic features including fleshy ears, full chin, and micrognathia. Before WES, a chromosome microarray was performed that revealed a 95-kb paternally inherited 5q23.2 duplication, including *CEP120M* and *CSNK1G3* genes.

Patient 2 has behavioral issues and is aggressive to her siblings. She also has a number of dysmorphic facial features, including fleshy earlobes, small nose, deep-set eyes, up-turned upper lip, short philtrum, and round face, and had a laryngeal cleft at birth. A chromosome microarray was normal.

DISCUSSION {#s3}
==========

Using clinical WES, we have identified two unrelated patients with novel de novo heterozygous predicted deleterious variants in the *PHIP* gene with a common clinical phenotype of developmental delay, intellectual disability, anxiety, hypotonia, poor balance, obesity, and dysmorphic facial features.

The phenotype of our two patients is similar to a previously reported patient with a de novo heterozygous nonsense mutation in *PHIP*, p.Y1149\* (c.3447T\>G), who has developmental delay, severe intellectual disability (IQ \< 50), obesity (weight \> +2 SD), and facial dysmorphisms ([@WEBSTERMCS001172C4]).

Nine patients with microdeletions spanning the 6q14.1 region including the *PHIP* gene have been reported with a similar phenotype including developmental delay, intellectual disability, hypotonia, and obesity ([@WEBSTERMCS001172C2]; [@WEBSTERMCS001172C24]). However, patients with microdeletions encompassing the *PHIP* gene have a number of additional clinical findings that do not overlap with the phenotype of our patients, probably because of the deletion of adjacent genes in 6q14. We suggest that the microdeletion data, our frameshift mutation, and the previously reported patient with a nonsense mutation support an autosomal dominant loss-of-function mechanism for disease caused by mutations in *PHIP*. *PHIP* is predicted to be sensitive to haploinsufficiency ([@WEBSTERMCS001172C10]).

*PHIP* produces at least three proteins through alternative splicing: PHIP1 (also known as DCAF14), PHIP, and NDRP ([Fig. 2](#WEBSTERMCS001172F2){ref-type="fig"}; [@WEBSTERMCS001172C6]; [@WEBSTERMCS001172C12]; [@WEBSTERMCS001172C20]). Domains of these proteins include a β-propeller-forming WD40 repeat domain, nuclear localization signals, a pleckstrin homology domain-binding region, and bromodomains ([@WEBSTERMCS001172C6]; [@WEBSTERMCS001172C20]). Notably, PHIP1 is the only protein product disrupted by all three variants. The two predicted deleterious variants we report are in the PHIP1 and NDRP protein-coding region, and the mutation described by [@WEBSTERMCS001172C4] falls in the PHIP1 and PHIP protein-coding region. It is possible that the phenotype observed in our patients is due to disruption of PHIP1 alone.

![(*A*) Schematic representation of *PHIP* protein products and predicted deleterious variants. *PHIP* produces at least three proteins through alternative splicing: PHIP1 (also known as DCAF14), PHIP, and NDRP. (*B*) *PHIP* sequence conservation across species. Underlined letter in sequences aligns with the p.F17S variant.](WebsterMCS001172_F2){#WEBSTERMCS001172F2}

PHIP1, also known as DCAF14 (DDB1- and CUL4-associated factor), is a member of the DCAF protein family ([@WEBSTERMCS001172C11]; [@WEBSTERMCS001172C15]). DCAFs act as substrate receptors for ubiquitin E3 ligases using a CUL4-DDB1 complex ([@WEBSTERMCS001172C9]; [@WEBSTERMCS001172C8]). The CUL4-DBB1 ubiquitin ligase binds to various substrate receptors to target specific proteins for proteolysis and is involved in a variety of regulatory pathways, including gene transcription, cell cycle, cell death, and embryonic development ([@WEBSTERMCS001172C8]; [@WEBSTERMCS001172C15]). The substrate(s) and protein targets of the CUL4-DDB1-PHIP1 complex are not yet known.

The role of PHIP1 as a substrate receptor for the CUL4-DDB1 complex may explain how the p.F17S variant causes protein dysfunction. At least seven DCAFs have α-helices close to the amino terminus that are important for DCAF-DDB1 binding ([@WEBSTERMCS001172C16]). This binding motif, termed H-box, is thought to facilitate DCAF-DDB1 interaction in part through hydrophobic interactions ([@WEBSTERMCS001172C16]). The amino-terminus α-helix of PHIP1, in which the missense variant is located, may function as an H-box ([Fig. 3](#WEBSTERMCS001172F3){ref-type="fig"}). The substitution of a hydrophobic amino acid, phenylalanine, for a hydrophilic amino acid, serine, could disrupt PHIP1-DDB1 binding.

![Depiction of the CUL4-DDB1 ubiquitin ligase complex and the role of the predicted PHIP1 H-box. Yellow lines indicate hydrophobic interactions between the PHIP1 H-box and DDB1. Ub, ubiquitin; E, ubiquitin-conjugating enzyme; R, RING finger protein. (Adapted from [@WEBSTERMCS001172C15].)](WebsterMCS001172_F3){#WEBSTERMCS001172F3}

CUL4, a member of the cullin-RING ubiquitin ligase family, is expressed in mammals as two paralogs, CUL4A and CUL4B ([@WEBSTERMCS001172C25]). *CUL4B* is encoded on the X Chromosome, and deficiency in males is associated with intellectual disability, seizures, aggressive outbursts, central obesity, muscle wasting, short stature, macrocephaly, and dysmorphic features including brachydactyly, macroglossia, pes cavus, and prominent upper lip ([@WEBSTERMCS001172C23]; [@WEBSTERMCS001172C25]). The phenotype of patients with *CUL4B* mutations overlaps with the phenotype of our patients. Because CUL4B and PHIP1 function in the same ubiquitin ligase pathway, the similarities support our suggestion that *PHIP* variants are causative of the phenotype in our patients.

PHIP1 is ubiquitously expressed in mice, with higher levels of expression in brain, pancreatic islet, and skeletal muscle cells ([@WEBSTERMCS001172C20]). The expression pattern is consistent with the neurologic and metabolic phenotypes in our patients. The obesity in these patients could be the result of disruption of PHIP1 effects on brain-mediated food intake and energetics. The insulin resistance observed could be secondary to obesity or mediated centrally. Through its pleckstrin homology domain-binding region, PHIP interacts with insulin receptor substrate 1 (IRS1) to propagate insulin signaling, leading to insulin-dependent mitogenesis and GLUT4 translocation to the plasma membrane because of cytoskeletal reorganization ([@WEBSTERMCS001172C7]). The expression pattern of *Phip1* in mice, the similar phenotype of our two patients, the previously reported patient with a *PHIP* mutation, and the overlapping phenotype of individuals with 6q14.1 microdeletions and *CUL4B* mutations collectively suggest that the mutation in *PHIP* is responsible for the phenotype observed in our patients and that the phenotype is probably caused by disruption of the ubiquitin ligase pathway due to loss of function of PHIP1.

METHODS {#s4}
=======

Whole-Exome Sequencing {#s4a}
----------------------

Genomic DNA was extracted from whole blood of affected children and their parents. Exome sequencing was performed on exon targets captured using the Agilent SureSelect Human All Exon V4 (50 Mb) kit (Agilent Technologies). The sequencing methodology and variant interpretation protocol has been described previously ([@WEBSTERMCS001172C22]). Variants were confirmed by Sanger sequencing. The general assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page (<http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/>).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The *PHIP* variants found in this study have been deposited in ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) under accession numbers SCV000282077 and SCV000282078. Raw WES data could not be deposited because of a lack of patient permission.
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